by MM360 Staff | Jun 2, 2025 | Uncategorized
Source: CureToday articles Dr. Guru Sonpavde discusses the CheckMate 901 trial evaluating Opdivo plus Yervoy for those with cisplatin-ineligible, metastatic urothelial carcinoma. Read More
by MM360 Staff | Jun 1, 2025 | Uncategorized
Source: ASCO Daily News Dr. John Sweetenham shares highlights from Day 3 of the 2025 ASCO Annual Meeting, including new research for the treatment of advanced renal cell carcinoma and 2 studies on novel approaches in non-small cell lung cancer. Transcript Dr. John...
by MM360 Staff | Jun 1, 2025 | Uncategorized
Source: CureToday articles Adjuvant Opdivo, cisplatin and radiotherapy improved DFS vs other treatment among those with locally advanced squamous cell carcinoma of the head and neck. Read More
by MM360 Staff | Jun 1, 2025 | Uncategorized
Source: CureToday articles Camizestrant and continued therapy with CDK4/6 inhibition benefits patients who present with ESR1-mutated, ER+, HER2– advanced breast cancer. Read More
by MM360 Staff | Jun 1, 2025 | Uncategorized
Source: CureToday articles Tecentriq and chemotherapy combination reduces the risk of death versus chemotherapy alone in deficient mismatch repair, stage 3 colorectal cancer. Read More
by MM360 Staff | May 31, 2025 | Uncategorized
Source: ASCO Daily News Dr. John Sweetenham shares highlights from Day 2 of the 2025 ASCO Annual Meeting, including new data on the treatment of ER+/HER2-negative breast cancer and potentially practice-changing results for patients with cutaneous squamous cell...
